Journal of Dermatological Treatment This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Patient preferences for treatment attributes in moderate-to-severe atopic dermatitis: a discrete choice experiment
Conclusions: Participants preferred AD treatments that maximize itch control while minimizing AE risks, whereas mode of administration had little impact on preferences. Understanding patients' preferences may help improve shared decision-making, potentially leading to enhanced patient satisfaction with treatment, increased engagement, and better clinical outcomes.PMID:38705585 | DOI:10.1080/09546634.2024.2345739 (Source: Journal of Dermatological Treatment)
Source: Journal of Dermatological Treatment - May 5, 2024 Category: Dermatology Authors: Steven R Feldman Annie Guerin Marjolaine Gauthier-Loiselle Ami J Claxton Nisha C Hazra Yan Meng Kirsten Gallant Sanjeev Balu Source Type: research

Rapid and sustained improvements in itch and quality of life with upadacitinib plus topical corticosteroids in adults and adolescents with atopic dermatitis: 52-week outcomes from the phase 3 AD Up study
Conclusions: Upadacitinib + TCS results in rapid, sustained improvements in burdensome AD symptoms and QoL.PMID:38697950 | DOI:10.1080/09546634.2024.2344589 (Source: Journal of Dermatological Treatment)
Source: Journal of Dermatological Treatment - May 2, 2024 Category: Dermatology Authors: Nina Magnolo Michael C Cameron Mona Shahriari Bob Geng Brian M Calimlim Henrique Teixeira Xiaofei Hu Yang Yang Yingyi Liu Shiyu Zhang Cristina Sancho Sanchez Katherine Altman Richard G Langley Source Type: research

Statement of retraction: evidence-based clinical practice guidelines for the management of psoriasis: systematic review, critical appraisal, and quality assessment with the AGREE II instrument
J Dermatolog Treat. 2024 Dec;35(1):2334685. doi: 10.1080/09546634.2024.2334685. Epub 2024 Apr 29.NO ABSTRACTPMID:38684214 | DOI:10.1080/09546634.2024.2334685 (Source: Journal of Dermatological Treatment)
Source: Journal of Dermatological Treatment - April 29, 2024 Category: Dermatology Source Type: research

Clinical course and disease burden of patients with generalized pustular psoriasis in Portugal: a multicenter retrospective cohort study
CONCLUSIONS: Our study demonstrates that GPP is a chronic, debilitating condition associated with systemic involvement, frequent flares, and hospitalizations, despite receiving multiple systemic treatments. Improved disease awareness and new treatments are needed to improve patient care and decrease the burden of the disease.PMID:38684228 | DOI:10.1080/09546634.2024.2345728 (Source: Journal of Dermatological Treatment)
Source: Journal of Dermatological Treatment - April 29, 2024 Category: Dermatology Authors: Tiago Torres Joana Antunes Ana Brasileiro Jo ão Alves Diana Bernardo Jos é Ramos Diogo Sousa Cristina Castro Ana Gusm ão Palmeiro Andr é Aparício Martins Joana Fazendeiro Matos B árbara Vieira Granja Pedro Ponte Gabriela Marques Pinto Paula Quirino Source Type: research

Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two Phase 3 trials
CONCLUSIONS: Improvement in itch and sleep interference due to itch is associated with improvement in the QoL of patients after treatment with lebrikizumab for moderate-to-severe AD.ClinicalTrials.gov registration NCT04146363 (ADvocate1) and NCT04178967 (ADvocate2).PMID:38679419 | DOI:10.1080/09546634.2024.2329240 (Source: Journal of Dermatological Treatment)
Source: Journal of Dermatological Treatment - April 28, 2024 Category: Dermatology Authors: Jennifer Soung Sonja St änder Jan Gutermuth Ignasi Pau-Charles Zach Dawson Fan Emily Yang Luna Sun Evangeline Pierce Hany Elmaraghy Linda Stein-Gold Source Type: research

Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study
CONCLUSIONS: Upadacitinib was therapeutically effective and tolerable for moderate-to-severe AD through 48 weeks in real-world clinical practice.PMID:38653561 | DOI:10.1080/09546634.2024.2344591 (Source: Journal of Dermatological Treatment)
Source: Journal of Dermatological Treatment - April 23, 2024 Category: Dermatology Authors: Teppei Hagino Hidehisa Saeki Eita Fujimoto Naoko Kanda Source Type: research